证券代码：600594 证券简称：益佰制药 公告编号：2024-041 贵州益佰制药股份有限公司 关于公司财务负责人变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、财务负责人辞职基本情况 近日，贵州益佰制药股份有限公司（以下简称"公司"）董事会收到公司副 总经理、财务负责人暨董事会秘书蒋先洪先生的书面辞职报告。蒋先洪先生因个 人原因，申请辞去公司财务负责人职务，蒋先洪先生的辞职报告自送达董事会之 日起生效。辞去财务负责人职务后，蒋先洪先生仍将在公司继续担任副总经理兼 董事会秘书职务。 公司及公司董事会对蒋先洪先生在担任财务负责人期间为公司发展做出的 贡献表示感谢。 二、聘任财务负责人情况 根据《中华人民共和国公司法》《上海证券交易所股票上市规则》《贵州益 佰制药股份有限公司章程》的相关规定以及公司经营发展需要，经公司总经理提 名，公司第八届董事会提名委员会资格审查，公司于 2024 年 9 月 6 日召开第八 届董事会第九次会议，以 6 票同意，0 票反对，0 票弃权的表决结果，审议通过 了《关于聘任公司财务负 ...

关于召开 2024 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600594 证券简称：益佰制药 公告编号：2024-040 贵州益佰制药股份有限公司 重要内容提示： 会议召开时间：2024 年 9 月 19 日 星期四 13:00-14:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动方式 投资者可于 2024 年 9 月 10 日（星期二）至 9 月 18 日（星期三）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过贵州益佰制药股份有 限公司（以下简称"公司"）邮箱（600594@gz100.cn）进行提问。公司将在说明 会上对投资者普遍关注的问题进行回答。 公司已于 2024 年 8 月 24 日 在 上 海 证 券 交 易 所 网 站 （http://www.sse.com.cn/）披露了《贵州益佰制药股份有限公 ...

证券代码：600594 证券简称：益佰制药 公告编号：2024-038 贵州益佰制药股份有限公司 关于以集中竞价交易方式回购公司股份进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2023/11/30 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2023 年 月 29 日至 2024 年 | 11 | 月 | 28 | 日 | 11 | | 预计回购金额 | 2,000 万元~4,000 万元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 | | | | | | | | □为维护公司价值及股东权益 | | | | | | | 累计已回购股数 | 5,037,400 股 | | | | | | | 累计已回购股数占总股本比例 | 0.64% | | | | | | | 累计已回购金额 | ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥1,168,191,423.50, a decrease of 21.05% compared to ¥1,479,701,367.04 in the same period last year[14]. - The net profit attributable to shareholders of the listed company was -¥106,493,434.06, representing a decline of 183.26% from a profit of ¥127,906,049.29 in the previous year[14]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥111,539,699.14, a decrease of 207.18% compared to ¥104,065,059.82 in the same period last year[14]. - Basic earnings per share for the first half of 2024 was -0.134 yuan, a decrease of 182.72% compared to the same period last year[15]. - Diluted earnings per share for the first half of 2024 was -0.134 yuan, reflecting a decrease of 182.72% year-over-year[15]. - The net profit attributable to shareholders for the first half of 2024 was significantly impacted by the suspension of Aidi injection and price reductions in collective procurement for certain products, leading to a substantial revenue decline[15]. - The company reported a significant increase in financial expenses by 383.14%, from ¥2,582,563.14 to ¥12,477,327.91, mainly due to reduced fiscal subsidies[48]. - The company reported a net loss of CNY 21,258,535.78 for the current period, compared to a profit of CNY 137,395,526.92 in the previous period[98]. Cash Flow and Assets - The net cash flow from operating activities was ¥203,096,744.36, showing a slight increase of 0.39% from ¥202,303,020.59 in the previous year[14]. - Total assets at the end of the reporting period were ¥4,405,858,145.33, a decrease of 4.16% from ¥4,597,253,863.18 at the end of the previous year[14]. - The company's total assets amounted to CNY 3,018,254,958.88, indicating a stable asset base despite fluctuations in cash flow[110]. - Cash and cash equivalents increased to CNY 760,224,074.48, up 8.67% from CNY 699,468,723.75 at the end of 2023[92]. - The company's cash and cash equivalents at the end of the period stood at CNY 341,554,784.13, down from CNY 383,897,198.80 at the end of the previous year[109]. Operational Highlights - The company operates in multiple therapeutic areas including oncology, cardiovascular, gynecology, pediatrics, orthopedics, and respiratory diseases[21]. - The healthcare services segment includes the operation and management of one general hospital and two specialized hospitals, enhancing the company's service capabilities[21]. - The company is expanding its product line in the health sector, focusing on traditional medicine and health products, including candies and plant-based beverages[21]. - The company is actively expanding its healthcare services, leveraging established doctor resources to enhance service quality and efficiency[22]. - The company has established a robust procurement system to ensure quality and efficiency, aiming to reduce procurement costs significantly[22]. Research and Development - The company emphasizes research and development, aiming to improve product quality and expand its market presence through innovative marketing strategies[21]. - The company faces significant R&D risks due to the high investment and long timeframes required for drug development, which may impact sales performance and lead to potential failures[54]. - The company is committed to enhancing R&D efficiency and increasing investment to mitigate risks associated with drug development and market competition[54]. - Research and development expenses increased to CNY 52,148,931.55 from CNY 48,369,912.16, representing an increase of 5.8%[99]. Market Position and Strategy - The company is transitioning from a modern traditional Chinese medicine manufacturer to a comprehensive pharmaceutical enterprise that includes chemical drugs, modern traditional Chinese medicine, and biological drugs[25]. - The company is focusing on innovation-driven strategies, enhancing core business advantages, and expanding its product line to improve market competitiveness[25]. - The company has built a professional marketing team, covering over 10,000 medical institutions nationwide, including more than 2,000 tertiary medical institutions[35]. - The company is exploring a combined sales model of self-operated teams and e-commerce to increase market share in the health product sector[25]. Regulatory and Compliance - The company has received administrative penalties from the Guizhou Provincial Drug Administration for not adhering to production quality management standards, resulting in a production suspension notice[77]. - The company has submitted a rectification report to the Guizhou Securities Regulatory Bureau, enhancing compliance training and internal control measures[78]. - The company was warned by the Shanghai Stock Exchange for failing to timely disclose the suspension of its main product's production, leading to regulatory scrutiny[78]. - The company is committed to improving information disclosure quality and compliance awareness among its management and staff[78]. Environmental Responsibility - The company is classified as a key pollutant discharge unit, with specific emissions data reported for wastewater and air pollutants[62]. - The company has implemented measures to ensure compliance with environmental standards, with no exceedances reported for wastewater discharge[62][63]. - The company continues to focus on environmental responsibility and compliance with local regulations regarding emissions and waste management[62][63]. - The company has established a wastewater treatment facility with a capacity of 2,000 m³/d, and the Chang'an Pharmaceutical Meian plant has a designed capacity of 800 m³/d, with 400 m³/d currently completed[66]. Shareholder and Governance - The company held two shareholder meetings during the reporting period, approving key proposals including the 2023 annual financial report and the profit distribution plan[57]. - The first extraordinary shareholder meeting in 2024 approved the election of independent directors and supervisors[58]. - There were significant changes in the board and management, including the resignation of the vice chairman and co-CEO, and the election of new independent directors and supervisors[59][60]. - The company has committed to enhancing corporate governance and protecting investor rights while fulfilling its social responsibilities[43].

证券代码：600594 证券简称：益佰制药 公告编号：2024-037 贵州益佰制药股份有限公司 关于计提 2024 年半年度相关资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、计提资产减值准备概述 注：本公告所有数值保留两位小数，若出现总数与各分项数值之和尾数不符 的情况，均为四舍五入原因所致。 （一）资产减值准备计提情况 1、存货跌价损失计提情况 为客观、公允地反映贵州益佰制药股份有限公司（以下简称"公司"）2024 年半年度经营状况，根据《企业会计准则》《企业会计准则第 1 号——存货》《企 业会计准则第 8 号——资产减值》《企业会计准则第 20 号——企业合并》《企业 会计准则第 39 号——公允价值计量》《公开发行证券的公司信息披露编报规则第 15 号——财务报告的一般规定(2023 年修订)》(证监会公告〔2023〕64 号)及公 司会计政策等相关规定，公司以 2024 年 6 月 30 日为资产负债表日，判断相关资 产是否存在减值迹象，并进行资产减值测试，根据减值测试结果，计提相关资产 ...

证券代码：600594 证券简称：益佰制药 公告编号：2024-036 贵州益佰制药股份有限公司 股票质押式回购交易延期购回公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 控股股东窦啟玲女士持有贵州益佰制药股份有限公司（以下简称"公司"） 股份数量 185,457,636 股，占公司总股本的 23.42%，控股股东窦啟玲女士持有 公司股份累计质押数量为 148,180,650 股，占其持股数量的 79.90%，占公司总 股本的 18.71%。 控股股东窦啟玲女士及其一致行动人窦雅琪女士累计质押股份数量为 148,180,650 股，占窦啟玲女士及其一致行动人窦雅琪女士合计所持公司股份的 79.79%，占公司总股本的 18.71%。 一、本次股份质押延期购回情况 近日，公司接到控股股东窦啟玲女士的通知，获悉其将所持有的公司部分股 份办理了股票质押延期购回业务，具体情况如下： 被质押股份不存在被用作重大资产重组业绩补偿等事项的担保或其他保障 用途情况。 2.股东累计质押股份情况 截至本公告披露日，上述股东及其 ...

证券代码：600594 证券简称：益佰制药 公告编号：2024-035 贵州益佰制药股份有限公司 关于以集中竞价交易方式回购公司股份进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2023/11/30 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2023 年 11 月 2024 | 日至 | 月 | 年 | 11 | 28 | 日 | 29 | | 预计回购金额 | 2,000 万元~4,000 万元 | | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | | | □用于转换公司可转债 | | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | | 累计已回购股数 | 5,037,400 股 | | | | | | | | | 累计已回购股 ...

证券代码：600594 证券简称：益佰制药 公告编号：2024- 034 贵州益佰制药股份有限公司 关于首次回购公司股份的公告 重要内容提示： | 回购方案首次披露日 | 2023/11/30 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2023 年 11 月 日至 2024 11 | 日 | 年 | 月 | 28 | 29 | | 预计回购金额 | 2,000 万元 万元~4,000 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | 累计已回购股数 | □为维护公司价值及股东权益 2,723,900 股 | | | | | | | 累计已回购股数占总股本比例 | 0.34% | | | | | | | 累计已回购金额 | 7,999,631 元 | | | | | | | 实际回购价格区间 | 2.89 元/股至 2.95 元/股 | | | | | | 一、回购股份的基本情况 贵州益佰制药股份有限公司（以下简称"公司"）于 2 ...

Financial Performance Forecast - The company expects a net profit attributable to the parent company for the first half of 2024 to be between -125 million yuan and -105 million yuan, indicating a loss compared to the same period last year [14]. - In the same period last year, the net profit attributable to the parent company was 127.91 million yuan, with a net profit of 104.07 million yuan after deducting non-recurring gains and losses [7]. - The company’s total profit for the first half of 2023 was 153.64 million yuan [17]. - The company reported earnings per share of 0.162 yuan in the previous period [10]. - The performance forecast period is from January 1, 2024, to June 30, 2024 [15]. Reasons for Expected Loss - The main reason for the expected loss is the cessation of production and sales of the main product, Aidi Injection, leading to a significant decline in revenue and profit [11]. - The decline in revenue is also attributed to price reductions for products such as L-Oplatin Injection, Ginkgo Biloba Injection, and Compound Scolopendra Capsule [18]. Forecast and Risk Disclosure - The earnings forecast is based on preliminary calculations by the company's finance department and has not been audited by a registered accountant [16]. - The company emphasizes that the forecast data is subject to change and the final financial data will be disclosed in the official half-year report [9]. - The company warns investors to be aware of investment risks due to the anticipated losses [9].

证券代码：600594 证券简称：益佰制药 公告编号：2024-032 贵州益佰制药股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2023/11/30 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 日~2024 年 2023 11 | 11 | 28 | 日 | 月 | 月 | 29 | | 预计回购金额 | 2,000 万元~4,000 万元 | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | | □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | 0 股 | | | | | | | | 累计已回购股数占总股本比例 | 0% | | | | | | | | ...